Roberto. Thanks,
higher experienced a largest Demand prior much XXXX. revenues products significant in and earlier, X% impressive last quarter, from the difficult genomics very our market, year. quarter resulting level year growth strong The likewise, which is discussed second remained at grew includes our increased our the molecular comparison in XXXX, given performance for has during consumer QX As prior generally over customer, in our than periods. the dramatically of which
the are consumer demand purchasing trends tied noticeable starting more in see annual shopping seasonal in primarily we retail in season. to uptick There patterns. to identifiable a promotional holiday addition, is In genomic events
As variable a from result, progression we expect to quarter-to-quarter. revenue see of more
best we growth still annual in Given our be the basis range the the progress compared XXXX quarterly to expect business importantly, vary. on double-digit it's as for in Most view full see progressions when that, to molecular continued our an can likely rate in growth to XXXX. year to with
solid molecular business Our and top first-time more orders XX are basis. XX% we very of About trailing purchasers strong, sales seeing showed of new and customers. QX both acquisitions on growth came from customers to and remains existing than growth a XX-month from customer XX XXX our
use multiyear have top The possible. our negotiate these as We've purchasing genomics multiyear now X aid customers have ability purchasing customers. to revenues of and XX agreements X been One of as We our to customers and multiyear should efforts products great both supply of priorities many top XXX including over in forward. XX arrangements. under made going accounts arrangements with of our progress our microbiome forecast products, has now
our of We increase between positive to the very continue lines for product a future. likely foreseeable is synergy this that and to type in is trend believe business
customers GenoFIND fulfillment customization also acquired new our X services. from We and
and GenoFIND We provide to the their customers our offerings. So of now, to of speeding significant XX by use quality half overall believe top value these customers services. the market our time our services improving
we side, quarter, commercial XX are good which test new X service that, very had providers. genomics in of a acquired the we On accounts,
growth quarter XX% of the academic We growth of revenue sequential also from in business, reported XXXX. year prior strong over the represents first our which XX%
This the expected second to this growth $X performance XX% market over million Pacific of represents quarter year. Asia The in Pacific quarter our the second represents year. continue of growth in the of revenue. throughout best is in type This with the over Asia last market remainder
Invitae this of the important in orders transactions a medical quarter new is genetic multiyear second we our Dx the testing more Initial was that serves Oragene under for industry. professionals shipping with agreement company the pharmaceutical researchers, agreement One and during completed the product. quarter. Invitae a supply began
of We DNA testing. of breed, saliva with also information Vet purchase canines PERFORMAgene Embark to provide for the closed from and an agreement health our the for traits through product collection
canine believe the positive are opportunity their impact We the are one excited a have it willing to business. This than lifetime. testing our of can often and about area the on money course have potential an over of on market their pets the represents dog interesting and health owners as of spend more pet
The growing and The year-over-year this collection in year. of both Europe, service North diversity with offerings, the products by over increasing of we in Our out our the XXX% quarter significant business usage overall to growth demand sales this prior America, past microbiome apparent Pacific. ninth we the growth with health period business driven with the was revenue where sales along where of XXXX. market, year QX XX of XXX% QX, Asia growth. up from our device is largely customers best its growth geographic of second microbiome and compared quarter posted in for ever in quarter and direct-to-consumer Middle posted sequentially by XX% the the the saw and quarter consecutive East microbiome the our This up fourth is sequential of
seeing pharmaceutical use number of wellness customers. of respect processed our also With companies companies an especially we demand by to are from of clinical both microbiome-focused services, device, in collection samples for increasing devices boutique repeat services We the increased OMNIgene lab from support and saw and trials.
microbiome have molecular purchasers microbiome commercial Importantly, X the these therapeutic academic purchasers Of XX XX collection in in quarter, X engaged their were top entities. customers, services. are both remainder service our of and purchasing moved microbiome trials lab X to Of commercial the and customers, into were XX development use and top and/or now clinical accounts research. top products diagnostic XX customers in purchasing are undertaking customers to are all of our offerings our and our second devices enable X support
meeting human So common have of all insights services by an range customers value increasingly the analyzing these that our actionable product customer in is offerings health are and and they they're pursuing needs. broad of products now What about we provide. microbiome the
given line could Moreover, are outpace in become the this that to organisms the to confident will individual, substantial same contributor day We collected years. multiple needed our changing that the microbiome. top business from the easily found in to test genomics due the volume the samples one be microbiome coming constantly a
For market about we opportunity. this this are reason, very excited
to Turning infectious disease.
Our business, strong XXX% with prior compared The primary for for was year quarter. up a delivered quarter growth business. our main period. the which reason revenues global HIV was growing for HIV performance the second business this Self-Test driver to the XX% The international was our
increase million second a this quarter, over first the we quarter year. the shipped X.X XX% During self-tests, of
know, over has of X out the of this tests you the program. STAR for periods, II approximately program. STAR we several Phase As from product demand million much of the million for have the To the shipped come X.X planned date, past
us Africa, a and more self-test Foundation. about we favorable XX for targeted marginalized in to important An sector various now populations, our initial Self-Test growth for early revenue agreement stimulating the is significant covers awareness our program, Latin and Asia, Self-Testing, This are purchasers during various remember HIV scale-up effectiveness countries demand non-STAR designed from our to America intended channels various shipments that pubic activities, the African serving in test. driver raise allow our serve pricing, self-testing with pilot support well came are West Asia, product. adoption to Self-Testing. In Sub-Saharan to between is pilots use number Central payments Examples over campaigns HIV program the XX public quarter. Support countries the see offer Africa, intended important of the majority countries include of HIV of to second Charitable self-testing which to STAR we that of our date, beginning To the Gates under sectors uptick the addition to in with countries. programs demonstrate interest, in It's programs in and Agreement the targeting health
calls, an channel prior in even the market agreement. many these market covered in pursue additional discussed by as are GATES in countries, As though continuing pharmacy we're the also to opportunities sales not
We continue a to World growth OraSure rapid HIV recently report for and over Health issued several landscape years. believe that significant represents UNITAID Self-Testing Organization HIV The and market the testing. a global opportunity on technology next
in to to the HIV people recognizing In otherwise The the about of end tests part to forecast get reach million procurement global that in business. market the to of from provide numbers HIV are report available states by XX.X outlook not to Obviously, risk, addition the and significant increase at testing report expected sectors the growth tests X and may XXXX. optimistic tested, suggests the who support XXXX. estimated public importance beyond both but evidence private stated the a they to of this Self-Testing for XXXX in further for that an are our further our million projections, up these
and government quarter, supply contract of prior as revenues HCV a a of primarily price a loss large result large heard nonrenewal the the NGO foreign of international competition. year from a QX for declined As you international as earlier, result customer of
a to remain funding business we discontinuing year, large also screening HCV in to Our down a Nevertheless, overall grant HIV and increased testing high, Interest business our was confident and NGO we're testing last delays believe future in to its remains seeing for programs of potential domestic future. due in the primarily growth. source compared for efforts. available funding near will it and be continue HCV the
testing we Here's Domestically, funding offering from companies that pharmaceutical grants. support seeing are why. are
in HIV-uninfected program elimination the to Gilead million with populations. $X be support December recently XXXX. program high-risk in expected The a announced grant to made is HIV-infected example, and of For awards budget HCV
should are bill also programs. recent test initiatives moving improved HCV seeing XXXX The support in for and for funding HIV that improve legislative included that programs available through March, We federal spending HCV testing. passed fiscal Congress funding
testing of there's Division order for to example, XX% the health a state address department. efforts Hepatitis received which an initiatives. local As Centers opioid by also Disease by and in of Viral Congress increase Control the we expect and We're to the Prevention and seeing HCV funding to bolster activities epidemic, include
hepatitis community. form, the era feasibility Finally, the veteran type positive Congress program to advancing bill a testing for prevalence gauge its may rapid our for Administration. attempt and believe in periods. obviously outreach this an these HCV that to VA veterans we a tests bill XXX,XXX Veterans future improve a would In with developments support rapid service are testing roughly types is to program Vietnam current outside to for and system and mandate organizations This a establish of strongly C national reach view -- establish this number funding in outreach
testing HCV to HCV of seeing in interest result front, geographies availability the international of various opportunities in the largely of a world. expand, a as We're number and treatment low-cost around On therapies. continues
growth demand customers reflects various increased from orders an existing products. compared purchased these is and to an This to XXXX. opportunities. that international pursue QX We'll increase timing our new our As where of HCV the sales revenues in continue and customers, XXX% in both in Africa, in Asia favorable example,
briefly Turning to operations.
focused supplier. on and only made -- much our in Canada capacity. effort the our As in year a Bethlehem, and We've also balancing good or Thailand not reminder past prior here we've so, on from but expanding over calls production progress
our best for remain competition, The I'd and caveat a the assessment strategy that This today with with from of that core the with an last like inventory work some long-term for We review and that products. our capabilities was the must trends address We few and is to This news modeling last. market key to our you themes changes of making recently potential of area endorsed completed I'll demand are several to final work includes confident we're board the shared of needed our our reasons. an meet future Today, review. share by competitive confidential month. business due work strategies. save
and including importantly, and businesses. and high infectious in the disease and global marketplace focus potential in growth and our eradication interest see growing these potential HIV biology significant we consumer microbiome Several and to systems the core funding appropriate signal in the principle most with ongoing underlying assets First growth strategy The molecular businesses trends, maximize for of opportunities our the of for and all the investment. is overarching our growth HCV, and core strengths. genomics,
external achieve entities will serving by of we may our are expect We and I targeting of this companies acquisition coming strategy making will become development consider addition that accretive. acquisition that earlier-stage in the will revenue-producing internal activities, the technologies. entities -- other established updates more the outcome more both developed evident to in less markets investments, and business the that external of In be updated months.
overarching the in now. you future share themes meantime, can with I some However,
business to On remains genomics the intend molecular and invest this we our side, overall core business. molecular key to and our central grow saliva strategy,
enhancement new collaborations portfolio This genomics of multiomics further at focus our expand our system on in apply on the focus and stakeholders. through businesses. programs, registrations microbiome testing core and HIV our look offerings, and end-to-end disease, franchises new to the and through introduction continue customization, to globally intend also also of We to HCV fulfillment, core expanding with our innovative and areas our infectious the of analytics laboratory our will that build services. with We'll strengths primarily service area biology. microbiome customers other and product both products we'll In in
professional protect and our product self-testing through HIV to performance improvements intend claims. enhanced grow and we businesses Additionally, and
we with our with relationships HCV, with portfolio customers our intend Beyond HIV existing product strengths our leverage product and our products. and existing expanding by to synergistics
we We to months our our you in goals. updating are our attention have implementation. I the strategic coming look review, focus pleased and strategy on completed on against to forward these progress can now detailed very
company the for is and deliver positioned enhance exciting opportunity results. conclusion, to is an a well affords The sheet time potential. financial growth continues solid to in with this That So us our combined strong balance OraSure.
before exciting We in growth days are have us, which the opportunities a of especially the of early their still organic potential, microbiome. number many of
external screen, the have and in a companies complementary basis. place on We infrastructure technologies evaluate or timely to acquire
Our new is other clear days, build in head say our and order development to endeavor the build busy development to ones existing relationships we completed strengths the are on priorities these will with our to and strategic stakeholders. work, and of bond Having our core business deepen least. customers our with new
will success. We products next the in putting to even continue valuations level. in outlook for now them advance level. and OraSure. and about a CEO impressed innovation here it's by and pieces culture crucial what months, do to our this can I'm and intend for company say our necessary with selective balance at gotten place the our management we of a the our while prioritizing company proceed. strength by to management company and know take work, sheet your I remaining And because hesitation, right to to the without rewards to other efforts then foster strategy by to I deeper the we the confident will believe more I'm continuing growth. have team the I of questions. that, I empowers their innovate have do our that we'll Operator, to team, that please the pursue I quality the that strong became the we More that pay. than X to take
